Literature DB >> 11341977

Activation of extracellular-regulated kinases by normal and mutant EGF receptors.

I A Lorimer1, S J Lavictoire.   

Abstract

Glioblastoma cells express a mutant EGF receptor (EGFRvIII) that has constitutive tyrosine kinase activity and enhances their tumorigenicity. Here we show that EGFRvIII promotes constitutive phosphorylation of extracellular regulated kinases (ERKs) in glioblastoma cells in the absence of EGF. EGFRvIII also promoted constitutive activation of phosphoinositide 3-kinase in these cells, as assessed by phosphorylation of protein kinase B/akt. As expected, phosphorylation of protein kinase B/akt was blocked by the phosphoinositide 3-kinase inhibitors wortmannin and LY294002. Less expectedly, we found that this treatment also blocked EGFRvIII-induced phosphorylation of ERKs. In contrast, ERK phosphorylation induced by EGF-activated normal EGF receptor in the same cells was largely unaffected by treatment with phosphoinositide 3-kinase inhibitors. This difference in behavior between the normal receptor and EGFRvIII was not due to differences in the levels of activated EGFRvIII and wild-type EGF receptor, as the two types of receptor were tyrosine phosphorylated to a similar extent under the experimental conditions used. EGFRvIII activation of ERKs was also sensitive to the phospholipase C inhibitor U73122, whereas ERK activation by normal EGF receptor was not. These results show that EGFRvIII and wild-type EGF receptor preferentially use different signaling pathways to induce ERK phosphorylation. The different mechanisms of ERK activation used by normal and mutant EGF receptors may be important in understanding the potent tumorigenic activity of EGFRvIII.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11341977     DOI: 10.1016/s0167-4889(00)00129-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

1.  E2F1-mediated repression of WNT5A expression promotes brain metastasis dependent on the ERK1/2 pathway in EGFR-mutant non-small cell lung cancer.

Authors:  Huanhuan Li; Fan Tong; Rui Meng; Ling Peng; Jiaojiao Wang; Ruiguang Zhang; Xiaorong Dong
Journal:  Cell Mol Life Sci       Date:  2020-10-19       Impact factor: 9.261

2.  Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.

Authors:  R Patel; S F Nagueh; N Tsybouleva; M Abdellatif; S Lutucuta; H A Kopelen; M A Quinones; W A Zoghbi; M L Entman; R Roberts; A J Marian
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

Review 3.  Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.

Authors:  Kimmo J Hatanpaa; Sandeep Burma; Dawen Zhao; Amyn A Habib
Journal:  Neoplasia       Date:  2010-09       Impact factor: 5.715

4.  Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.

Authors:  Daniel R Premkumar; Esther P Jane; Ian F Pollack
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.

Authors:  Li Li; Amalia Dutra; Evgenia Pak; Joseph E Labrie; Rachel M Gerstein; Pier Paolo Pandolfi; Larry D Recht; Alonzo H Ross
Journal:  Neuro Oncol       Date:  2008-09-23       Impact factor: 12.300

6.  Activated protein C: a potential cardioprotective factor against ischemic injury during ischemia/reperfusion.

Authors:  Jingying Wang; Ji Li
Journal:  Am J Transl Res       Date:  2009-07-15       Impact factor: 4.060

Review 7.  Ligand-Independent EGFR Signaling.

Authors:  Gao Guo; Ke Gong; Bryan Wohlfeld; Kimmo J Hatanpaa; Dawen Zhao; Amyn A Habib
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

8.  Lupeol evokes anticancer effects in oral squamous cell carcinoma by inhibiting oncogenic EGFR pathway.

Authors:  Sanchita Rauth; Sudipta Ray; Sayantan Bhattacharyya; Debapriya Ghosh Mehrotra; Neyaz Alam; Goutam Mondal; Partha Nath; Asoke Roy; Jaydip Biswas; Nabendu Murmu
Journal:  Mol Cell Biochem       Date:  2016-05-20       Impact factor: 3.396

9.  Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.

Authors:  Claire Marie-Elisabeth Sauvageot; Jessica Leigh Weatherbee; Santosh Kesari; Susan Elizabeth Winters; Jessica Barnes; Jamie Dellagatta; Naren Raj Ramakrishna; Charles Dean Stiles; Andrew Li-Jen Kung; Mark W Kieran; Patrick Yung Chih Wen
Journal:  Neuro Oncol       Date:  2008-08-05       Impact factor: 12.300

Review 10.  Applications of emerging molecular technologies in glioblastoma multiforme.

Authors:  Hari R Kumar; Xiaoling Zhong; John A Sandoval; Robert J Hickey; Linda H Malkas
Journal:  Expert Rev Neurother       Date:  2008-10       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.